Bicycle Therapeutics has been selected for one invited lecture and three poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR), being held from April 14 to April 18 in Chicago, Illinois.
A presentation describing the discovery of BT1718 will be given by Bicycle’s Chief Scientific Officer Nicholas Keen, Ph.D. in the New Drugs on the Horizon Session. BT1718 is a Bicycle Toxin Conjugate offering a completely new approach to the treatment of cancer, and it is currently being evaluated in a Phase I/IIa study sponsored by Cancer Research UK, the world’s leading charity dedicated to cancer research.
“We are honored to have been selected to describe the discovery of BT1718 in the New Drugs on the Horizon session and look forward to sharing our preclinical data as well as providing a clinical update” said Dr. Keen. “BT1718 represents a new and highly differentiated approach to the treatment of cancer and is being developed through a unique collaborative partnership with Cancer Research UK, which provides important access to world-class operational infrastructure and strong drug development expertise.”
In the three poster presentations, Bicycle will present new data on its rapidly expanding preclinical pipeline, including two posters on the development of BT5528, a Bicycle Toxin Conjugate targeting EphA2, a tumour antigen highly expressed in difficult to treat cancers associated with poor prognosis. The company will also present new data describing the discovery and chemical optimisation of the first fully synthetic CD137 agonist, representing a new class of multimeric Bicycle T-cell modulators.